Polaryx Therapeutics, Inc.
PLYX Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$1.85
KIRA · Stoqly’s AI analyst, in plain words
- Polaryx Therapeutics, Inc. lost $9.0M in fiscal 2025.
Market cap
$89.3M
P/E
—
Revenue
—
Net income
−$9.0M
Free cash flow
—
Operating margin
—
Polaryx Therapeutics, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$9.0M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Polaryx Therapeutics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 24, 2026
- Legal name
- Polaryx Therapeutics, Inc.
- CIK
- 0002075320
Polaryx Therapeutics, Inc. · PLYX
Results and finances
The last 2 fiscal years. Amounts in USD.
| Fiscal year | FY24 | FY25 |
|---|---|---|
| Sales and profit | ||
| Net income | −$30.4M | −$9.0M |
| Diluted EPS | −$0.89 | −$0.20 |
| Cash | ||
| Cash from operations | −$2.6M | −$3.9M |
| Share count change | — | 32.8% |
| Debt and strength | ||
| Cash and short-term investments | $4.6M | $5.1M |
| Shareholders' equity | $4.7M | $4.6M |
| Current ratio | 17.3x | 8.5x |
| Returns and quality | ||
| Return on equity | −644.2% | −193.7% |
| Return on tangible equity | −644.2% | −196.8% |
| Altman Z'' | −41.6 | −59.3 |
Insiders bought, 12 months
$0.4M
2 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Polaryx Therapeutics, Inc. · PLYX
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $1.85 a share, the company is worth $89.3M.
Source: SEC EDGAR XBRL filings (CIK 0002075320). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.